P1061: INDIRECT TREATMENT COMPARISONS OF FEDRATINIB VERSUS NAVITOCLAX PLUS RUXOLITINIB: EFFECT ON SPLEEN VOLUME AND SYMPTOMS IN RUXOLITINIB-EXPOSED MYELOFIBROSIS PATIENTS

Detalles Bibliográficos
Autores principales: Abraham, P., Liao, X., Chevli, M., Smith, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Posters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430144/
http://dx.doi.org/10.1097/01.HS9.0000847112.18637.3d
_version_ 1784779671993319424
author Abraham, P.
Liao, X.
Chevli, M.
Smith, S.
author_facet Abraham, P.
Liao, X.
Chevli, M.
Smith, S.
author_sort Abraham, P.
collection PubMed
description
format Online
Article
Text
id pubmed-9430144
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-94301442022-08-31 P1061: INDIRECT TREATMENT COMPARISONS OF FEDRATINIB VERSUS NAVITOCLAX PLUS RUXOLITINIB: EFFECT ON SPLEEN VOLUME AND SYMPTOMS IN RUXOLITINIB-EXPOSED MYELOFIBROSIS PATIENTS Abraham, P. Liao, X. Chevli, M. Smith, S. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9430144/ http://dx.doi.org/10.1097/01.HS9.0000847112.18637.3d Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Posters
Abraham, P.
Liao, X.
Chevli, M.
Smith, S.
P1061: INDIRECT TREATMENT COMPARISONS OF FEDRATINIB VERSUS NAVITOCLAX PLUS RUXOLITINIB: EFFECT ON SPLEEN VOLUME AND SYMPTOMS IN RUXOLITINIB-EXPOSED MYELOFIBROSIS PATIENTS
title P1061: INDIRECT TREATMENT COMPARISONS OF FEDRATINIB VERSUS NAVITOCLAX PLUS RUXOLITINIB: EFFECT ON SPLEEN VOLUME AND SYMPTOMS IN RUXOLITINIB-EXPOSED MYELOFIBROSIS PATIENTS
title_full P1061: INDIRECT TREATMENT COMPARISONS OF FEDRATINIB VERSUS NAVITOCLAX PLUS RUXOLITINIB: EFFECT ON SPLEEN VOLUME AND SYMPTOMS IN RUXOLITINIB-EXPOSED MYELOFIBROSIS PATIENTS
title_fullStr P1061: INDIRECT TREATMENT COMPARISONS OF FEDRATINIB VERSUS NAVITOCLAX PLUS RUXOLITINIB: EFFECT ON SPLEEN VOLUME AND SYMPTOMS IN RUXOLITINIB-EXPOSED MYELOFIBROSIS PATIENTS
title_full_unstemmed P1061: INDIRECT TREATMENT COMPARISONS OF FEDRATINIB VERSUS NAVITOCLAX PLUS RUXOLITINIB: EFFECT ON SPLEEN VOLUME AND SYMPTOMS IN RUXOLITINIB-EXPOSED MYELOFIBROSIS PATIENTS
title_short P1061: INDIRECT TREATMENT COMPARISONS OF FEDRATINIB VERSUS NAVITOCLAX PLUS RUXOLITINIB: EFFECT ON SPLEEN VOLUME AND SYMPTOMS IN RUXOLITINIB-EXPOSED MYELOFIBROSIS PATIENTS
title_sort p1061: indirect treatment comparisons of fedratinib versus navitoclax plus ruxolitinib: effect on spleen volume and symptoms in ruxolitinib-exposed myelofibrosis patients
topic Posters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430144/
http://dx.doi.org/10.1097/01.HS9.0000847112.18637.3d
work_keys_str_mv AT abrahamp p1061indirecttreatmentcomparisonsoffedratinibversusnavitoclaxplusruxolitinibeffectonspleenvolumeandsymptomsinruxolitinibexposedmyelofibrosispatients
AT liaox p1061indirecttreatmentcomparisonsoffedratinibversusnavitoclaxplusruxolitinibeffectonspleenvolumeandsymptomsinruxolitinibexposedmyelofibrosispatients
AT chevlim p1061indirecttreatmentcomparisonsoffedratinibversusnavitoclaxplusruxolitinibeffectonspleenvolumeandsymptomsinruxolitinibexposedmyelofibrosispatients
AT smiths p1061indirecttreatmentcomparisonsoffedratinibversusnavitoclaxplusruxolitinibeffectonspleenvolumeandsymptomsinruxolitinibexposedmyelofibrosispatients

Ejemplares similares